Nelson Kenneth Warwick III
Known title: DirectorCIK: 0001981293
Associated companies
Transaction History
| BEAT | ▲ Buy | Grant | 17,241 | $0 | 2/9/2026 | View on chart |
| BEAT | ▲ Buy | Grant | 33,185 | $0 | 6/12/2024 | View on chart |
| BEAT | ▲ Buy | Grant | 23,961 | $0 | 7/13/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
HeartBeam Receives FDA Breakthrough Designation for Heart Attack Test
HeartBeam Inc. announced that its Home Heart Attack Test system has been granted FDA Breakthrough Device designation. The designation recognizes the product’s potential to improve early detection of heart attacks at home. The company’s technology could expand its market presence and support future regulatory approvals. The news adds to the company’s positive momentum amid a mixed market session.
HeartBeam Receives FDA Breakthrough Designation for Heart Attack Test. HeartBeam Inc. announced that its Home Heart Attack Test system has been granted FDA Breakthrough Device designation. The designation recognizes the product’s potential to improve early detection of heart attacks at home. The company’s technology could expand its market presence and support future regulatory approvals. The news adds to the company’s positive momentum amid a mixed market session.